<DOC>
	<DOCNO>NCT02293993</DOCNO>
	<brief_summary>To evaluate tolerability pharmacokinetics SGI-110 administer subcutaneously Japanese patient acute myeloid leukemia ( AML ) .</brief_summary>
	<brief_title>Phase 1 Study SGI-110 Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Male female patient diagnosis AML ( WHO classification 2008 ) . Patients , 20 year age old , unresponsive standard chemotherapy relapse follow standard chemotherapy Patients , 65 year age old , eligible standard intensive chemotherapy Patients ECOG performance status ( PS ) 0 2 Patients adequate organ function Women childbearing potential must pregnant breast feeding ( pregnancy test perform Screening ) . Women child bear potential men female partner child bear potential must practice two medically acceptable method birth control must become pregnant father child receive treatment SGI110 3 month follow last dosing . Patients undergone prior allogeneic hematopoietic stem cell transplantation must evidence active graftversus host disease ( GVHD ) must immunosuppressive therapy â‰¥2 week prior IMP administration . Patients acute promyelocytic leukemia accompany ( 15 ; 17 ) ( q22 ; q12 ) ( PML/RARA ) karyotype abnormality ( include variant type APL ) Patients multiple cancer ( except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free least 3 year ) Subjects lifethreatening illness AML MDS , uncontrolled medical condition organ system dysfunction , investigator 's opinion , could compromise subject 's safety , put study outcome risk . Patients poorly control arrhythmia , Class 3 4 cardiac disease define New York Heart Association Functional Classification Patients symptomatic central nervous system involvement .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>